Bay Colony Advisory Group Inc d b a Bay Colony Advisors Sells 1,602 Shares of Johnson & Johnson (NYSE:JNJ)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lessened its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,806 shares of the company’s stock after selling 1,602 shares during the period. Johnson & Johnson accounts for 1.0% of Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ investment portfolio, making the stock its 16th biggest position. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Johnson & Johnson were worth $3,399,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. RKL Wealth Management LLC lifted its position in Johnson & Johnson by 2.1% during the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares during the period. Geller Advisors LLC raised its holdings in Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after buying an additional 648 shares during the last quarter. Simon Quick Advisors LLC raised its holdings in Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after buying an additional 6,537 shares during the last quarter. Lokken Investment Group LLC raised its holdings in Johnson & Johnson by 1.6% in the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after buying an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP raised its holdings in Johnson & Johnson by 13.4% in the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on JNJ shares. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Citigroup lifted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Sanford C. Bernstein decreased their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $182.42.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $173.43 on Monday. The firm has a 50 day moving average of $176.32 and a 200 day moving average of $171.47. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $453.43 billion, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.60 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is currently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the transaction, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. Insiders sold a total of 300,750 shares of company stock worth $52,311,677 over the last three months. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.